Mednet Logo
HomeRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

What factors lead you to recommend a JAK inhibitor as second-line therapy in a patient with radiographic axSpA who has had a primary non-response to a TNF inhibitor, before trying an IL-17 inhibitor?

2 Answers

Mednet Member
Mednet Member
Rheumatology · Cedars-Sinai Medical Center

This is an excellent question which requires not just a treatment plan but also a revelation of how we should be making patient management decisions in Spondyloarthritis (SpA). My initial reaction is that primary non-response to a TNFi is not the usual story; if this truly happens, I recommend re-ev...

Is anifrolumab safe to use in patients with a history of malignancy?

1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Alabama Birmingham

Anifrolumab is not formally contraindicated in patients with a history of malignancy, but I would use it with individualized risk assessment.The United States Food and Drug Administration (FDA) label states that the effect of anifrolumab on malignancy development is unknown and recommends weighing t...

Can you use bisphosphonates in a patient with osteoporosis who has had prior avascular necrosis of TMJ due to steroid use?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · Penn Medicine

Due to the rarity of MRONJ, and significantly high fracture risk from osteoporosis, prior history of osteonecrosis is not considered an absolute contraindication for bisphosphonate use. Clinical picture is important is weighing this decision. If the patient is very high risk, anabolic therapy is app...

In patients with a history of retinal vein occlusion, how should the risk of recurrent thromboembolic events influence the selection of osteoporosis therapies?

3
2 Answers

Mednet Member
Mednet Member
Endocrinology · William Jennings Bryan Dorn Department Of Veterans Affairs Medical Center

The FDA-approved prescribing information for raloxifene explicitly lists retinal vein thrombosis alongside deep vein thrombosis and pulmonary embolism as contraindications.

For a pediatric patient with Takayasu arteritis with persistent enhancement and mild progression on imaging after recent transition to tocilizumab (2 months), would you continue tocilizumab therapy, increase to q2 week dosing, or transition to cyclophosphamide?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Georgetown University

Would add to the methotrexate and Steroids-shortened interval of the tocalizamab -followed by moving to Cytoxan. There is less experience with B Cell targeted treatment such as Rituxan or obintuzamab for CD 19, or CD 20

How do you interpret treatment response in the DISCOVER-2 Trial when patients were allowed to remain on up to 10mg of prednisone equivalent for disease control while on guselkumab?

3 Answers

Mednet Member
Mednet Member
Rheumatology · University of Washington in Seattle

If patients were on less than or equal to prednisone 10 mg, they could continue that in the background during the trial, but note that only 20% of patients were on prednisone, a much lower figure than a typical rheumatoid arthritis trial, which is consistent with the point that rheumatologists shy a...

Is there any role for immunosuppressive therapy in patients with primary Sjogren's disease with severe pulmonary artery hypertension without ILD findings?

2 Answers

Mednet Member
Mednet Member
Rheumatology · Tidalhealth

PAH (WHO Class I PH) in/and SJD is not a common relation, and as such would Rx as we Rx regarding PAH in PSS? The pathophysiology of PSS is, at least in part, a vasculopathy that SJD may not share. The question is, however, specific regarding Primary SJD and the assumption then is that this is not a...

How often are you performing CT screening in CVID patients to screen for ILD?

3
1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Medical University of South Carolina

CT once every 1-2 years, depending on symptoms and PFTs. PFTs, including DLCO, are annually performed.

Would you consider anti-IL-5 therapy (mepolizumab or benralizumab) to either prevent or treat the more severe manifestations of eosinophilic granulomatosis with polyangiitis, such as "infiltrative" (e.g., cardiomyopathy, pulmonary infiltrates, or gastroenteritis) or "vasculitic" (e.g., neuropathy, palpable purpura, or glomerulonephritis)?

1
2 Answers

Mednet Member
Mednet Member
Pulmonology · E Town Lung Specialists Psc

Yes, I would consider early starting biologics for infiltrative EGPA.

Does SI joint erosion on MRI pelvis push you to use TNF inhibitors over NSAIDs as first line for axial spondyloarthritis?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Wisconsin Madison

A decision to consider TNFi (or another targeted therapy) over initial NSAID therapy depends primarily on disease severity, symptom burden, and impact on quality of life, presence of significant peripheral disease (where csDMARDs have already failed or resulted in side effects), contraindications or...